Category: 1834-27-1

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1834-27-1,6-Chloro-4-methylpyridazin-3(2H)-one,as a common compound, the synthetic route is as follows.

Intermediate VIII6-Chloro-2,4-dimethyl-2H-pyridazin-3-one Methyl iodide (1.3 mL) was added to a mixture of 6-chloro-4-methyl-2H-pyridazin-3-one (2.70 g) and K2CO3 (3.40 g) in N,N-dimethylformamide (27 mL). The resulting mixture was stirred at ambient temperature overnight. Then, water was added and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with water and brine and dried (MgSO4). After removal of the solvent, the title compound was obtained as a solid.Yield: 2.97 g (100% of theory); Mass spectrum (ESI+): m/z=159/161 (Cl) [M+H]+.

1834-27-1, As the paragraph descriping shows that 1834-27-1 is playing an increasingly important role.

Reference：
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2012/108578; (2012); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

1834-27-1, 6-Chloro-4-methylpyridazin-3(2H)-one is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 6-chloro-4-methylpyridazin-3-ol (Intermediate X17; 500 mg, 3.46mmol) in DCM (20.3 mL) and pyridine (1 mL, 3.46 mmol) was treated with (3,5-dimethoxyphenyl)boronic acid (1.26 g, 6.92 mmol), Cu(OAc)2 (1.26 g, 6.92 mmol), and pyridine 1-oxide (1 .32 g, 13.8 mmol). The resulting mixture was stirred open to the atmosphere overnight at ambient temperature. The reaction mixture was diluted with DCM (100 mL) and filtered. The filtrate was washed with water (2 x 30 mL), and the organics were dried over anhydrous Na2SO4(), filtered and concentrated under vacuum. The crude residue was precipitated from MeOH to cleanly afford the title compound (780 mg, 80%). MS (apci) m/z = 281.1 (M+H), 283.0 [(M+H)+2] (with Cl pattern).

1834-27-1, The synthetic route of 1834-27-1 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; ARRAY BIOPHARMA, INC.; ANDREWS, Steven W.; BLAKE, James F.; COOK, Adam; GUNAWARDANA, Indrani W.; HUNT, Kevin W.; METCALF, Andrew T.; MORENO, David; REN, Li; TANG, Tony P.; (263 pag.)WO2017/70708; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

1834-27-1, 6-Chloro-4-methylpyridazin-3(2H)-one is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate VIII6-Chloro-2,4-dimethyl-2H-pyridazin-3-one Methyl iodide (1.3 mL) was added to a mixture of 6-chloro-4-methyl-2H-pyridazin-3-one (2.70 g) and K2CO3 (3.40 g) in N,N-dimethylformamide (27 mL). The resulting mixture was stirred at ambient temperature overnight. Then, water was added and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with water and brine and dried (MgSO4). After removal of the solvent, the title compound was obtained as a solid.Yield: 2.97 g (100% of theory); Mass spectrum (ESI+): m/z=159/161 (Cl) [M+H]+., 1834-27-1

1834-27-1 6-Chloro-4-methylpyridazin-3(2H)-one 164886, apyridazine compound, is more and more widely used in various fields.

Reference：
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2012/108578; (2012); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1834-27-1,6-Chloro-4-methylpyridazin-3(2H)-one,as a common compound, the synthetic route is as follows.

To a mixture containing 6-chloro-4-methylpyridazin-3(2H)-one (250 mg, 1.729 mmol) and K2CO3 (598 mg, 4.32 mmol) in DMF (2.5 mL) was added ethyl iodide (0.210 mL, 2.59 mmol). The reaction mixture was stirred at room temperature for 22 h. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (3×40 mL). The combined extracts were washed with 10% LiCl (2×20 mL) and saturated aqueous NaCl solution (1×20 mL), dried (Na2S04), filtered and concentrated to afford crude product. The crude product was dissolved in a small amount of DCM and charged to an ISCO silica gel 12 g ISCO column which was eluted over a 10 min gradient with 0%-100% hexanes/ethyl acetate to afford 6-chloro-2-ethyl-4-methylpyridazin-3(2H)-one (250 mg, 1.448 mmol, 84% yield), m/z (173, M+H). LCMS MH+: 173. HPLC Ret. Time 0.70 min. Method Bl . NMR (400 MHz, CHLOROFORM-d) delta 7.06 (q, J=1.2 Hz, 1H), 4.17 (q, J=7.2 Hz, 2H), 2.21 (d, J= 2 Hz, 3H), 1.37 (t, J=7.2 Hz, 3H).

1834-27-1, 1834-27-1 6-Chloro-4-methylpyridazin-3(2H)-one 164886, apyridazine compound, is more and more widely used in various fields.

Reference：
Patent; BRISTOL-MYERS SQUIBB COMPANY; DYCKMAN, Alaric J.; DODD, Dharmpal S.; HAQUE, Tasir Shamsul; WHITELEY, Brian K.; GILMORE, John L.; (192 pag.)WO2019/28302; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1834-27-1,6-Chloro-4-methylpyridazin-3(2H)-one,as a common compound, the synthetic route is as follows.

A solution of 6-chloro-4-methylpyridazin-3-ol (Intermediate X17; 0.50 g, 3.4 mmol) in DCM (20 mL) was treated with (5-(methoxycarbonyl)-2-methylphenyl)boronic acid (1.0 g, 5.2 mmol), Cu(OAc)2 (1.2 g, 6.9 mmol), pyridine 1-oxide (327 mg, 3.44 mmol) and pyridine (1.1 g, 14 mmol). The resulting mixture was stirred at ambient temperature open to the atmosphere for one overnight. The reaction mixture was diluted with DCM (100 mL) and washed with water (2 x 30 mL). The organic extracts were dried over anhydrous Na2SO4(), filtered and concentrated under vacuum. The crude residue was purified by silica gel flash chromatography (2-55% EtOAc/hexane as the gradient eluent) to afford the title compound (2.99 g, 99% yield). MS (apci) m/z = 293.0 (M+H), 295.0 [(M+H)+2] (with Cl pattern)., 1834-27-1

As the paragraph descriping shows that 1834-27-1 is playing an increasingly important role.

Reference：
Patent; ARRAY BIOPHARMA, INC.; ANDREWS, Steven W.; BLAKE, James F.; COOK, Adam; GUNAWARDANA, Indrani W.; HUNT, Kevin W.; METCALF, Andrew T.; MORENO, David; REN, Li; TANG, Tony P.; (263 pag.)WO2017/70708; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem